Common Contracts

Licensing agreement for ESETEC-based production of antibody fragment PB2452

License Agreement • June 14th, 2024

• Contract Type
  License Agreement
• Filed
  June 14th, 2024

PhaseBio obtains the right to use both WACKER’s ESETEC-based production strain and WACKER’s ESETEC technology to manufacture and commercialize the antibody fragment.